Accept Rs 700-cr from UAE or compensate us: Flood-ravaged Kerala tells Modi govt

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.

Mangaluru, Jul 15: A septuagenarian from Bantwal taluk died due to coronavirus infection at a hospital in the city taking the covid-19 death toll in Dakshina Kannada to 54.

The deceased was a 73-years-old and a resident of Kasaba village in Vittal, Bantwal. Recently eight members of his family were tested positive for covid-19 including his son.

He was admitted to a hospital in Mangaluru where he was tested positive for the virus. He did not respond to the treatment and breathed his last, sources said.

The final rites were carried out by a team of trained activists of Popular Front of India (PFI) at a designated graveyard. All necessary precautions were taken by the authorities concerned and police during the funeral.

New Delhi, Feb 13: Ashoka Buildcon on Thursday said it has emerged as the lower bidder for a highway project worth Rs 1,035.5 crore in Karnataka.

The project entails four laning of a section of NH-206 in the state.

Ashoka Buildcon had submitted its bid to National Highways Authority of India for the project to be built on hybrid annuity mode under Bharatmala Pariyojana, it said in a BSE filing.

"The company emerged as the lowest bidder at the financial bid opening meeting held on February 13," Ashoka Buildcon said.

The quoted bid project cost for the project is Rs 1,035.50 crore, it added.

The company's stock was trading at Rs 103.05, down 2.78 per cent, on the BSE.